Genmab A/S (CPH: GMAB)
Denmark
· Delayed Price · Currency is DKK
1,462.00
+8.00 (0.55%)
Dec 20, 2024, 4:59 PM CET
Genmab Employees
Genmab had 2,204 employees as of December 31, 2023. The number of employees increased by 544 or 32.77% compared to the previous year.
Employees
2,204
Change (1Y)
544
Growth (1Y)
32.77%
Revenue / Employee
7.53M DKK
Profits / Employee
1.78M DKK
Market Cap
92.87B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Novo Nordisk A/S | 64,319 |
Coloplast A/S | 16,639 |
Demant A/S | 21,623 |
Zealand Pharma A/S | 253 |
H. Lundbeck A/S | 5,681 |
H. Lundbeck A/S | 5,681 |
ALK-Abelló A/S | 2,824 |
Ambu A/S | 5,196 |
Genmab News
- 9 days ago - Genmab A/S: Circling Back On This Complicated Story - Seeking Alpha
- 11 days ago - Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 13 days ago - Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 14 days ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis - Business Wire
- 14 days ago - Genmab Is Too Attractive To Ignore - Seeking Alpha
- 14 days ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 19 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 19 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire